



eTheRNA Announces Relocation and Expansion of R&D Facility

GENT, BELGIUM, April 5, 2022 – eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased to announce the relocation of its R&D group to a new and larger site in Gent, Belgium.

The upgraded R&D facility is in the Zwijnaarde Science Park, where a cluster of biotech companies are located, and includes state-of-the-art laboratories together with allied services. The increased capacity available will allow eTheRNA’s research departments to enhance their investigations on a variety of mRNA and lipid nanoparticles for R&D applications, resulting in improved control and faster production cycles.

Stefaan De Koker, eTheRNA VP of Discovery, stated: “We are excited that this move gives us the opportunity to upgrade our R&D facility, allowing us to expand our activities and accomplish the ambitious goals that we have set for our research and development programs. This new facility makes it possible for us to strengthen our capabilities across the board, and we intend to leverage it fully to achieve our company milestones.”

The new office is located at Frieda Saeystraat 1B, 3rd floor, 9052 Zwijnaarde, Gent, Belgium.

About eTheRNA

eTheRNA is an mRNA technology discovery and development company with a full platform of integrated capabilities including: mRNA construct design and optimization; proprietary lipid nanoparticle (LNP) formulations which have demonstrated organ-specific distribution preclinically; process development and manufacturing capabilities for mRNA drug substance (gram GMP scale); and proprietary LNP / final product formulation technologies, including a lyophilized thermostable formulation in advanced development. With a focus on immune modulation and T Cell stimulation, eTheRNA is pursuing internal development programs to validate its core technologies and enable strategic partnerships in a range of geographic markets and therapeutic areas. eTheRNA is backed by a global syndicate of leading investors and is headquartered in Belgium with offices in New York and Hong Kong. To learn more, visit www.etherna.be.

For more information, please contact:

eTheRNA
Johanna Madero
media@etherna.be